With OMA, the commercial stakeholders can collaborate more closely with NICE for general enquiries relating to adoption of new drugs, devices and diagnostics by the National Health Service
The approved medicines include trastuzumab (Herceptin) for stomach cancer, radium 223 (Xofigo) and abiraterone (Zytiga) for prostate cancer, and nintedanib (Ofev) for idiopathic pulmonary fibrosis (a long term
The firm has enrolled the patients using suprachoroidal space (SPS) drug administration in the trial, which is designed to assess CLS-TA to treat macular edema associated with non-infectious
Gamida will use the money to advance its clinical programs, including the development of NiCord, an experimental treatment for patients with high risk hematological malignancies or blood cancers
The company said that the drug was being explored for the treatment of high-risk atherosclerotic cardiovascular disease. Lilly Bio-Medicines senior vice president and president David Ricks said: "We’re
The regulator has granted the filing accelerated assessment, under which it intends to provide a scientific opinion on the submission in a reduced time frame of 150 days.
Under the expanded deal, the firms will work together to develop and commercialize up to three anti-PD-1 based bispecific antibodies for cancer treatments over the next ten years,
The study is assessing Liposomal Grb-2, combined with low-dose cytarabine (LDAC) chemotherapy in patients with advanced AML. The company has started enrollment into Cohort eight, which will complete
Opdivo can be used for treatment of NSCLC with progression on or after platinum-based chemotherapy. According to the company, patients with epidermal growth factor receptor (EGFR) or anaplastic
Adheron has developed a new technology that disrupts immune cell adhesion through Cadherin-11 (Cad-11), a cell surface protein, to develop potential treatments for various inflammatory and autoimmune diseases.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.